Mumbai, Feb. 5 -- The approved Abbreviated New Drug Application (ANDA) is the first protease inhibitor (PI)-based single-tablet regimen (STR) available for the treatment of adults and adolescents (aged >= 12 years) with HIV-1 infection.

The company stated that it is the exclusive first-to-file for this product. This product will be manufactured at the company's Nagpur facility in India.

Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company's con...